title: Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study.
abstract: In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer).
authors.affiliation: Metropolitan Urology, Jeffersonville, IN, USA.
authors.forename: Kelly Marie
authors.initials: KM
authors.lastname: Gollar
authors.forename: Douglas G
authors.initials: DG
authors.lastname: Young
authors.forename: James
authors.initials: J
authors.lastname: Bailen
authors.forename: Weizhong
authors.initials: W
authors.lastname: He
authors.forename: Sergio
authors.initials: S
authors.lastname: Forero-Schwanhaeuser
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011788:Quality of Life; D011812:Quinuclidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D057566:Self Report; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000451:nursing / Q000523:psychology
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate